
Plexus (PLXS) Stock Forecast & Price Target
Plexus (PLXS) Analyst Ratings
Bulls say
Plexus Corp demonstrated a strong financial performance with a 15% year-over-year increase in new program wins in the Healthcare/Life Sciences segment, amounting to $130 million. The company's return on invested capital (ROIC) improved to 13.8%, up from 11.8% quarter-over-quarter, highlighting effective management of investments. Additionally, Plexus reported a significant turnaround in free cash flow, reaching $27 million compared to a negative $32 million in the prior year, and has raised its FY25 free cash flow outlook to $100 million, indicating robust future financial health.
Bears say
Plexus Corp experienced a decline in overall revenue, with a 1% year-over-year decrease to $976 million, falling short of previous guidance and market expectations. The company's guidance for FQ2 indicates stagnation in revenue growth, with a significant anticipated decline in the Industrial sector which cannot be compensated by gains in SemiCap. Additionally, free cash flow dropped substantially from $194 million in FQ4 to $27 million in FQ1, raising concerns about the company's financial performance and sustainability.
This aggregate rating is based on analysts' research of Plexus and is not a guaranteed prediction by Public.com or investment advice.
Plexus (PLXS) Analyst Forecast & Price Prediction
Start investing in Plexus (PLXS)
Order type
Buy in
Order amount
Est. shares
0 shares